Patient-Reported Outcomes (PROs) in Patients Switching to Teriflunomide From a Prior Disease-Modifying Therapy (DMT): Results From the Phase 4 Teri-PRO Study

Patricia K Coyne,1 Bhupendra Khati,2 Keith R Edwards,3 Steve Cavalier,4 Pascal Ruif,4 Sandrine Brette,5 Prashant Kulkarni,6 Ralf Gold,7 for the Teri-PRO Trial Group

1Stony Brook University, Stony Brook, NY, USA; 2Center for Neurological Disorders at Wheaton Franciscan Healthcare, Milwaukee, WI, USA; 3Multiple Sclerosis Center of Northeastern New York, Latham, NY, USA; 4Sanofi Genzyme, Cambridge, MA, USA; 5Sanofi Genzyme, Chilly-Mazarin, France; 6Axial, Boulogne-Billancourt, France; 7Cytel Statistical Software and Services, Pune, Maharashtra, India; 8St. Joseph Hospital, Ruhr University Bochum, Bochum, Germany

CONCLUSIONS

Quality of Life

- Adequate Markov transition probabilities were calculated in the model.

Statistical Analysis

- All patients who received 1 dose of teriflunomide were included in the analysis.
- In the analysis, a change in one or more domains is defined as a meaningful difference in the scores.
- Scores remained stable in switchers regardless of prior DMT received (Figure 1B).
- Improvement in TSQM scores was significantly improved at Week 48 across all domains in switchers regardless of prior DMT or other DMTs (Figure 1B).
- Treatment satisfaction was significantly improved at Week 48 across all domains in switchers regardless of prior DMT or other DMTs (Figure 1B).

RESULTS

Study Design and Patients

- Teri-PRO was a prospective, global, multicenter, single-arm, open-label study.
- Patients were treatment-naïve or re-challenged patients.
- Patients were treatment-naïve or re-challenged patients.
- All patients were treated with teriflunomide for 1 year or more.
- The study design and eligibility criteria have been presented previously.

Teri-PRO was a prospective, global, multicenter, single-arm, open-label study

Recruitment:
- Treatment satisfaction was significantly improved at Week 48 across all domains in switchers regardless of prior DMT or other DMTs (Figure 1B).
- Treatment satisfaction was significantly improved at Week 48 across all domains in switchers regardless of prior DMT or other DMTs (Figure 1B).

Figure 1A: Baseline TSQM Scores by Week 48 in All Patients

Figure 1B: Treatment Satisfaction by TSQM Domain Over the Course of the Teri-PRO Study

Figure 2A: Baseline MSPS Scores by Week 48 in All Patients

Figure 2B: Treatment Satisfaction by MSPS Domain Over the Course of the Teri-PRO Study

Figure 3A: Baseline Total MusiQoL Score by Week 48 in All Patients

Figure 3B: Treatment Satisfaction by Total MusiQoL Score Over the Course of the Teri-PRO Study

Figure 4A: Baseline Total TSQM Score by Week 48 in All Patients

Figure 4B: Treatment Satisfaction by Total TSQM Score Over the Course of the Teri-PRO Study

Figure 5A: Baseline Global Satisfaction Score by Week 48 in All Patients

Figure 5B: Treatment Satisfaction by Global Satisfaction Score Over the Course of the Teri-PRO Study

Quality of Life

- Total MFS scores remained low and stable over the course of the study in both switchers and patients receiving another DMT.
- Total MFS scores remained low and stable over the course of the study in both switchers and patients receiving another DMT.

Patient-Reported Disability

- Total MFS scores remained low and stable over the course of the study in both switchers and patients receiving another DMT.
- Total MFS scores remained low and stable over the course of the study in both switchers and patients receiving another DMT.

Acknowledgments and Disclosures

- Commercial support was received for the development of this manuscript; the development of the figures; and the editing and design of the manuscript.
- The study was approved by the Institutional Review Board/Independent Review Board at each site.
- Sanofi Genzyme, Cambridge, MA, USA; 4Axial, Boulogne-Billancourt, France; 7Cytel Statistical Software and Services, Pune, Maharashtra, India; 8St. Joseph Hospital, Ruhr University Bochum, Bochum, Germany

Presented at the 69th Annual Meeting of the American Academy of Neurology (AAN), April 22-28, 2017, Boston, MA, USA

References